Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Novartis AGNYSE: NVS

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of $3.27B fell 18.8% year over year, behind the -6.4% change in trailing-twelve-month net income. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at +32.5% a year.

Context

  • Net income amounted to 25.6% of revenue in FY2025, up 2.6 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 12 analysts of $17.42B (+24.0%) for the fiscal year ending Dec 2026, a step up from the +17.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.27B+3.5% QoQ
Last fiscal yearDec 2025
$14.06B+17.7% YoY
LTMJun 2026
$12.76B-6.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.8%+10.1%+28.9 pp
1 year+17.7%+24.0%+6.2 pp
3-year CAGR+32.5%+14.6%-17.8 pp
5-year CAGR+12.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
14.06B USD
Year-over-year change
+17.7%
4-year CAGR
-11.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -6.4% is the 6th highest of 11, against a peer median of -6.1%.
  • Net income amounts to 22.9% of revenue for NVS, versus a peer median of 16.6%.
NVS Competitors
Net Income for NVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 116.44B DKK+4.8%+22.6%35.3%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$9.27B USD+83.1%+3.6%18.9%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
GILDGilead Sciences, Inc.LTM Jun 2026$5.24B USD-17.0%+22.8%17.2%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
SNYSanofiLTM Jun 2026€3.96B EUR-46.8%-11.2%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding NVS) —-6.1%+5.8%16.6%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income22.91B6.05B8.57B11.94B14.06B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
Deferred Income Tax1.63B1.13B551M1.7B(361.84M)
Stock-Based Compensation700M791M865M1.04B0
Change in Working Capital(73M)(796M)(369M)(706M)(3.08B)
Accounts Receivables(352M)(397M)(1.5B)(931M)(1.13B)
Inventory(102M)(560M)(546M)(225M)34.17M
Accounts Payables(111M)(181M)479M(105M)(274.4M)
Other Working Capital492M342M1.2B555M(1.71B)
Other Non-Cash Items(15.68B)359M(3.44B)(2.43B)3.27B
Operating Cash Flow15.07B14.24B14.46B17.62B19.24B
Capital Expenditures(2.56B)(2.24B)(2.75B)(3.81B)(1.56B)
Acquisitions (Net)20.46B(864M)(3.57B)(3.83B)(3.01B)
Purchases of Investments(16.59B)(34.81B)(747M)(3.65B)(304.55M)
Sales of Investments2.74B39.49B11.6B3.7B2.19B
Other Investing Activities(1.34B)(1.43B)(624M)(2.38B)140.72M
Investing Cash Flow4.21B1.47B5.6B(7.51B)(4.9B)
Debt Repayment(5.67B)(2.59B)(1.94B)4.39B2.72B
Common Stock Issued000027.14M
Common Stock Repurchased(3.06B)(10.65B)(8.72B)(8.33B)(9.26B)
Dividends Paid(7.37B)(7.51B)(7.26B)(7.62B)(7.86B)
Other Financing Activities(169M)181M3.63B(177M)(577.95M)
Financing Cash Flow(16.26B)(20.56B)(14.28B)(11.74B)(14.94B)
Effect of Forex Changes(266M)(32M)100M(298M)579.07M
Net Change in Cash2.75B(4.89B)5.88B(1.93B)(24M)
Free Cash Flow12.52B12B11.71B13.81B17.69B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.